What stands out from the research is that awareness is currently highest among people already engaged in weight loss or GLP-1 treatment conversations
The STEP 1 trial (Wilding et al., The Lancet, 2021) showed an average weight loss of 14.9% over 68 weeks versus 2.4% in the placebo group a landmark result that established semaglutide as the benchmark for GLP-1 weight loss
It is critical that state policies addressing the rise in polysubstance use and its link to increased risk of overdose span across prevention, harm reduction, and treatment strategies
GLP-1s are a class of medications originally used to treat type 2 diabetes
Pillar 1: Stabilize Your Mast Cells (Turn Off the Faucet) This is the foundational step most people skip
Yes Treatment Length 5 to 10 Minutes Downtime None Locations Offered: Lees Summit & Overland Park Chronic fatigue Autoimmune concerns Skin disorders Low energy Signs of aging Consultation Every person is different, and we treat you that way